Sign In
Buy INO
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
INOVIO Announces Pricing of $25 Million Public Offering
07:30am, Thursday, 03'rd Jul 2025
PLYMOUTH MEETING, Pa. , July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote
INOVIO Announces Proposed Public Offering
04:16pm, Wednesday, 02'nd Jul 2025
PLYMOUTH MEETING, Pa. , July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
07:00am, Tuesday, 01'st Jul 2025
LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of Dav
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript
07:05pm, Tuesday, 13'th May 2025
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical O
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Tuesday, 13'th May 2025
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Tuesday, 13'th May 2025
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification
Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)
07:37pm, Friday, 09'th May 2025
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Confer
INOVIO to Present at Upcoming Scientific and Investor Conferences
08:05am, Wednesday, 30'th Apr 2025
PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-r
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
08:05am, Tuesday, 29'th Apr 2025
PLYMOUTH MEETING, Pa. , April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a
Bet on These 5 Top-Ranked Stocks With Rising P/E
08:40am, Monday, 21'st Apr 2025
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
Inovio (INO) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 09'th Apr 2025
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
INOVIO to Present at Upcoming Scientific Conferences
08:05am, Wednesday, 09'th Apr 2025
PLYMOUTH MEETING, Pa. , April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
10:35am, Tuesday, 01'st Apr 2025
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
08:48pm, Tuesday, 18'th Mar 2025
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
04:05pm, Tuesday, 18'th Mar 2025
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufact
